Pyropheophorbide-α Methyl Ester-mediated Photodynamic Therapy Induces Apoptosis and Inhibits LPS-induced Inflammation in RAW264.7 Macrophages
Overview
Authors
Affiliations
Background: This study aimed to determine the effect of pyropheophorbide-α methyl ester (MPPa)-mediated photodynamic therapy (MPPa-PDT) on the apoptosis and inflammation of murine macrophage RAW264.7 cells.
Methods: Uptake and subcellular localization of MPPa was detected by flow cytometry and confocal fluorescence microscope. Cell viability was assessed by CCK-8; ROS levels were assessed by DCFH-DA. Cell apoptosis was measured by flow cytometry and Hoechst 33342 staining, whereas mitochondrial membrane potential was detected by JC-1 staining. Secretion of tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) was determined using ELISA kits. Caspase-3, cleaved caspase-3, procaspase-9, cleaved caspase-9, PARP, cleaved PARP, Bcl-2, Bax, NF-κB p-p65, p-IKKα/β, and p-IκBα were measured by western blotting. Nuclear factor κB (NF-κB)-p65 nuclear translocation was observed by immunofluorescence.
Results: MPPa -PDT influenced cell viability in a light dose-dependent manner. It induced ROS formation and RAW264.7 cell apoptosis. It also increased the expression of cleaved caspase-3, cleaved caspase-9, cleaved PARP and Bax, decreased the expression of Bcl-2. While TNF-α, IL-1β, and IL-6 increased in LPS group (model of inflammation), it deceased in LPS-MPPa-PDT group. NF-κB p-p65, p-IKKα/β, and p-IκBα had higher expression in LPS group while that reduced in LPS-MPPa-PDT group. Simultaneously, MPPa-PDT inhibited nuclear translocation of NF-κB-p65 caused by LPS.
Conclusions: MPPa-PDT can induce apoptosis and attenuate inflammation in mouse RAW264.7 macrophages, thereby suggesting a promising therapy for atherosclerosis.
Trends and future directions of autophagy in osteosarcoma: A bibliometric analysis.
Shang J, Zhao F, Xie L, Wang Y, Li B, Jin C Open Med (Wars). 2024; 19(1):20241080.
PMID: 39655055 PMC: 11627063. DOI: 10.1515/med-2024-1080.
Photodynamic Therapy for Atherosclerosis: Past, Present, and Future.
Lin Y, Xie R, Yu T Pharmaceutics. 2024; 16(6).
PMID: 38931851 PMC: 11206729. DOI: 10.3390/pharmaceutics16060729.
Mahdizade Ari M, Amirmozafari N, Darbandi A, Afifirad R, Asadollahi P, Irajian G Front Chem. 2024; 12:1384344.
PMID: 38817441 PMC: 11138352. DOI: 10.3389/fchem.2024.1384344.
Application of Photodynamic Therapy in Cardiology.
Wanczura P, Aebisher D, Klosowicz M, Mysliwiec A, Dynarowicz K, Bartusik-Aebisher D Int J Mol Sci. 2024; 25(6).
PMID: 38542180 PMC: 10969994. DOI: 10.3390/ijms25063206.
Photodynamic Therapy for Atherosclerosis.
Mytych W, Bartusik-Aebisher D, Los A, Dynarowicz K, Mysliwiec A, Aebisher D Int J Mol Sci. 2024; 25(4).
PMID: 38396639 PMC: 10888721. DOI: 10.3390/ijms25041958.